Maker of scientific instruments (mass spectrometry, NMR, X-ray) for life-science research, applied and clinical microbiology markets.
Maker of scientific instruments (mass spectrometry, NMR, X-ray) for life-science research, applied and clinical microbiology markets.
Sells high-priced laboratory instruments to universities, government labs, drugmakers and hospitals, then earns repeat income from service contracts, upgrades and consumables on the installed base. Orders depend on research budgets, notably public research funding at universities. It has expanded into spatial biology and diagnostics through acquisitions, including NanoString in 2024.
Moat: narrow (installed base, switching costs, IP / patents). Specialized, technically differentiated instruments with an installed base among research and clinical microbiology labs.
Headquarters: Billerica, Massachusetts, USA · Founded: 1960 · Employees: 11,085
Size Bruker (BRKR) is a United States Health Care company (Medical Specialties) with a market value of $9.66B, the 790th largest of 3,085 United States companies the cockpit tracks. Shares closed at $63.26 on 18 Nov 2026.
Performance Over six months the shares gained 42.9%, against +25.4% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 2.2% over the last twelve months (peer median +7.2%); the operating margin is 10.1% (peer median 16.1%).
Valuation It trades at 27.0× forward earnings against a peer median of 19.9× (6th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points below its cost of capital (10.5% WACC).
Backlog Backlog (remaining performance obligations) was $2.78B at 30 Sep 2026, up 34% on a year earlier — 0.8 years of trailing revenue. Backlog detail →
Short interest Short interest is 7.4% of the free float (30 Oct 2026).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.51B | $3.44B | $3.37B | $2.96B | $2.53B |
| Revenue growth | — | +2% | +14% | +17% | — |
| Gross profit | $1.69B | $1.64B | $1.66B | $1.52B | $1.31B |
| EBITDA | $582M | $500M | $564M | $597M | $548M |
| Net income | -$123M | -$8.60M | $113M | $427M | $297M |
| Free cash flow | $245M | $43.3M | $136M | $243M | $145M |
| Capital expenditure | $97.1M | $90.8M | $115M | $107M | $129M |
| Total debt | $1.71B | $2.04B | $2.25B | $1.38B | $1.27B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bruker BRKR | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Agilent Technologies A | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% |
| Waters WAT | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BRKR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.1% | +5.0% | 6th highest of 21 |
| 6-month return | +42.9% | +25.4% | 4th highest of 21 |
| Distance from 52-week high | -8.3% | -11.7% | 9th highest of 21 |
| Revenue growth (TTM) | +2.2% | +7.2% | 5th lowest of 21 |
| Operating margin | 10.1% | 16.1% | 6th lowest of 21 |
| Forward P/E | 27.0× | 19.9× | 6th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 25.4% | 10.0% | 4th most demanding of 21 |
| Growth delivered (Del g) | +11.6% | +9.9% | 7th highest of 21 |
| Hurdle (Req g minus delivered) | +13.8 pp | +1.9 pp | 5th most demanding of 21 |
| ROIC minus cost of capital | -3.4 pp | +2.5 pp | 3rd lowest of 21 |
| EV / EBITDA | 19.3× | 12.7× | 4th most expensive of 20 |
| Net debt / EBITDA | 2.7× | 0.5× | 5th most indebted of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| Cooper Companies (The) COO | United States | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.6B | 0% | +4% | 19% | 13.8× | 13.1% | +10.3% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| bioMerieux BIM.PA | France | $11.8B | +26% | -3% | 15% | 20.2× | 8.6% | +5.5% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% | +5.6% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 55.7× | 30.7% | +20.2% |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% | -0.7% |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
Bruker reported $2.78B of remaining performance obligations at 30 Sep 2026, up 34% from a year earlier and flat from the previous quarter. That is 0.8 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.